Preclinical in vivo evaluation of a gonococcal multivalent vaccine containing antigens identified by CASS
Published
Sept 22, 2025
Source
Shea K Roe, Bo Zheng, Sunita Gulati, Caroline Genco, Sanjay Ram, Paola MassariÂ
Abstract
Neisseria gonorrhoeae, causative agent of the human sexually transmitted infection gonorrhea, is a significant global health concern because of increasing antimicrobial resistance and the lack of an effective vaccine. Recent ecological analyses have shown a reduced incidence of gonorrhea in recipients of detergent-extracted outer membrane vesicle (OMV)-containing meningococcal vaccine, which has contributed to identification of shared, protective antigens. Previously, our group has developed an immunobioinformatics-based pipeline (CASS, Candidate Antigen Selection Strategy) for identification of gonococcal hypothetical proteins expressed during human natural mucosal infections, as novel vaccine candidates.
Posted by
Levy CIMAR